Other Events ·
Innate Pharma completed enrollment in the Phase 1 dose escalation study of IPH4502, a Nectin-4 exatecan antibody-drug…
IPHYFInnate Pharma SA
Innate Pharma completed enrollment in the Phase 1 dose escalation study of IPH4502, a Nectin-4 exatecan antibody-drug conjugate (ADC). The study included 76 patients across France and the United States. Preliminary data readout from these patients is expected by year-end 2026 to guide dose optimization. Early observations indicate a favorable safety profile with limited hematological toxicity and objective responses in patients with urothelial carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Innate Pharma is a biotechnology company developing immunotherapies for cancer patients.